Poseida Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma

Poseida Therapeutics
Poseida Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma
Efficacy and safety continue to be a major advantage, with a very high response rate, no dose limiting toxicities and only a single incidence of suspected cytokine release syndrome. P-BCMA-101 clinical data as well as preclinical data from MUC1C and PSMA solid tumor programs and BCMA allogeneic program presented at the CAR-TCR Summit
September 5, 2018